跳至主要内容
临床试验/NCT02082028
NCT02082028已完成不适用

Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only

Sanofi23 个研究点 分布在 1 个国家目标入组 241 人开始时间: 2012年6月27日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Sanofi
入组人数
241
试验地点
23
主要终点
Change in HbA1c levels from baseline

研究概览

简要总结

To demonstrate the superiority of a chronic care model (SINERGIA model) supported by the Self Monitoring of Blood Glucose with BGStar over usual care in improving glycemic control at 12 months in patients with type 2 diabetes not treated with insulin.

详细描述

The planned study duration is 36 months (9 quarters). The estimated duration of screening/enrollment will be 12 months, followed by the 12-month experimental phase, plus the 12-month follow-up in the observational phase.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females
  • Age ≥ 45 years
  • Type 2 diabetes
  • First access at the diabetes clinic
  • Any diabetes duration
  • HbA1c >7.0 and ≤ 9.0%
  • Already treated with any oral antidiabetic agent (OAD) or requiring the initiation of therapy with OAD
  • Patients not using SMBG or using SMBG with a frequency ≤1 test/week
  • Written informed consent

排除标准

  • Treatment with insulin or need to start insulin regimens or continuous sub-cutaneous insulin infusion at the first access; Refusal or inability to give informed consent to participate in the study;
  • Conditions / situations such as:
  • Patients with short life expectancy;
  • Patients with conditions/concomitant diseases making them non evaluable for the primary efficacy endpoint according to physician's judgment;
  • Requirement for concomitant treatment that could bias primary evaluation (i.e. corticosteroid treatment);
  • Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, study coordinator, other study site staff or relative of study site staff thus considered directly involved in the conduct of the study;
  • Current addition/abuse of alcohol or drugs;
  • Patients with any mental condition rendering them unable to understand the nature, scope, and possible consequences of the study;
  • Pregnant or breast-feeding women;
  • Patients living too far from investigational center or other conditions reducing the adherence to the protocol; Subjects unlikely or unable to comply with the Protocol requirements (e.g. illiterate, uncooperative, unable to return for follow-up visit, unable to use BGStar unlikely to complete the study)

结局指标

主要结局

Change in HbA1c levels from baseline

时间窗: baseline to 12 months

次要结局

  • Variation in body weight from baseline(at 12 months and 24 months)
  • Variation in waist circumference from baseline(at 12 months and 24 months)
  • Variation in blood pressure from baseline(at 12 months and 24 months)
  • Variation in lipid profile from baseline(at 12 months and 24 months)
  • PDM (Patient involvement in the Decision Making process) questionnaire(at 12 months and 24 months)
  • Percentage of participants with HbA1c ≤7.0%(at 12 months and 24 months)
  • Quality of life: SF12 (Health Survey) questionnaire(at 12 months and 24 months)
  • ADDQOL (Audit of Diabetes-Dependent Quality of Life)(at 12 months and 24 months)
  • DTSQ (Diabetes Treatment Satisfaction Questionnaire)(at 12 months and 24 months)
  • ABIM-14 (American Board of Internal Medicine satisfaction questionnaire)(at 12 months and 24 months)
  • PHCO (Patient Health Care Orientation) questionnaire(at 12 months and 24 months)
  • Participants satisfaction with SMBG meter assessed by Visual Analog Scale (VAS)(at 12 months and 24 months)

研究者

发起方
Sanofi
申办方类型
Industry
责任方
Sponsor

研究点 (23)

Loading locations...

相似试验